Unitiol-Binergia (Unithiol-Binergia)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceSodium dimercaptopropanesulfonateSodium dimercaptopropanesulfonate
Similar drugsTo uncover
  • Unithiol
    solution w / m PC 
    NOVOSIBHIMFARM, OJSC     Russia
  • Unithiol
    solution w / m PC 
    StatusPharm, LLC     Russia
  • Unithiol
    solution w / m PC 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Unithiol
    solution w / m PC 
    PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC     Russia
  • Unithiol
    solution w / m PC 
    ELLARA, LTD.     Russia
  • Unithiol
    solution w / m PC 
    Kursk Biofactory - BIOK, FKP     Russia
  • Unitiol-Binergia
    solution w / m PC 
    BINERGIYA, CJSC     Russia
  • Unithiol-Ferein
    solution
    BRYNTSALOV-A, CJSC     Russia
    • Dosage form: & nbspsolution for intramuscular and subcutaneous administration
    Composition:
    1 ml of the preparation contains: active substance - sodium dimercaptopropanesulfonate monohydrate (unitiol) 50 mg; excipient: water for injection.
    Description:Transparent colorless or pinkish liquid with a faint smell of hydrogen sulfide.
    Pharmacotherapeutic group:Complexing agent
    ATX: & nbsp

    V.03.A.B   Antidotes

    Pharmacodynamics:
    Complexing agent, has detoxification effect. Active sulfhydryl groups, reacting with thiol poisons and forming nontoxic compounds with them, restore the functions of the body's enzyme systems,affected by poison. Increases the excretion of certain cations (especially Cu2 + and Zn2 +) from metal-containing cell enzymes.

    With diabetic polyneuropathy reduces the irritative pain syndrome, improves the condition of the peripheral nervous system and normalizes the permeability of capillaries.

    Pharmacokinetics:

    When parenteral administration is rapidly absorbed into the blood. The maximum concentration in blood plasma (C max) is achieved through 15-30 minutes after intramuscular injection. Half-life (T1/2) - 1-2 hours. Excreted by the kidneys, mainly in the form of products of incomplete or partial oxidation, in part - in unchanged form.

    Indications:Intoxication with arsenic, mercury, bismuth, chromium and cardiac glycosides; hepatocerebral dystrophy (Wilson-Westfal-Konovalov disease); diabetic polyneuropathy; chronic alcoholism (as part of complex therapy), alcoholic delirium (in the composition integrated therapy).
    Contraindications:

    Hypersensitivity, hepatic insufficiency, arterial hypertension, pregnancy, lactation, children under 18 years.

    Dosing and Administration:

    Intramuscularly, subcutaneously.At an intoxication with arsenic - 250-500 mg (5-10 ml of the preparation), at the rate of 50 mg / 10 kg, on the first day - 3-4 times, on the second day - 1-3 times, in the subsequent - 1-2 times .

    When poisoning with mercury compounds - according to the same scheme for 6-7 days. Treatment is carried out until the signs of intoxication disappear.

    With digital intoxication in the first two days, 250-500 mg (5-10 ml of the drug) are administered 3-4 times a day, then 1-2 times a day until the cardiotoxic effect stops. In hepatocerebral dystrophy - intramuscularly 250-500 mg (5-10 ml of the drug) daily or every other day; course of treatment - 25-30 injections; if necessary, repeat after 3-4 months.

    With chronic alcoholism, 150-250 mg (3-5 ml of the drug) are prescribed 2-3 times a week. To relieve delirium - once 200-250 mg (4-5 ml of the drug).

    With diabetic polyneuropathy - intramuscularly, 250 mg (5 ml of the drug), treatment course - 10 injections.

    Side effects:Nausea, vomiting, dizziness, tachycardia, pallor of the skin, increased blood pressure, anxiety.
    Overdose:

    In the recommended doses and on the evidence of overdose phenomena does not arise.

    If the recommended therapeutic Doses 10 times are observed dyspnea, hyperkinesis, inhibition, lethargy, deafness, short-term convulsions.Treatment: symptomatic therapy.
    Interaction:It is not recommended simultaneous use of Unithiol with preparations, which include heavy metals and alkalis, t. there is a rapid decomposition of Unithiol.
    Special instructions:In case of acute poisoning, additional medical measures are carried out (gastric lavage, oxygen therapy, dextrose administration, etc.)
    Effect on the ability to drive transp. cf. and fur:

    Data confirming the influence of Unitiol-Binergia on the ability to engage in potentially hazardous activities requiring increased attention, no.

    Form release / dosage:

    Solution for intramuscular and subcutaneous administration 50 mg / ml.

    Packaging:

    5 ml of the drug into neutral glass ampoules.

    5 ampoules are placed in a contour plastic package (tray) made of a polyvinylchloride film or a polyethylene terephthalate film.

    Five ampoules are placed in a contour mesh box made of a polyvinylchloride film or a polyethylene terephthalate film and aluminum foil of a printed lacquered or packaging material.

    1.2 contour plastic packages (pallets) or contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Packing for hospitals:

    25, 50, 100 contour plastic packages (pallets) or contour mesh packages together with an equal number of instructions for use are placed in a cardboard box.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.
    Shelf life:

    5 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-001672
    Date of registration:24.04.2012 / 15.09.2014
    The owner of the registration certificate:BINERGIYA, CJSC BINERGIYA, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp28.12.15
    Illustrated instructions
      Instructions
      Up